This standard is based on NG42.
This standard should be read in conjunction with QS123 and QS13.
Introduction Introduction
This quality standard covers the assessment and management of motor neurone disease. For more information see the motor neurone disease topic overview.
Why this quality standard is needed
Motor neurone disease (MND) is a neurodegenerative condition affecting the brain and spinal cord.
MND is characterised by the degeneration of primarily motor neurones, leading to muscle weakness.
Presentation of the condition varies. It can be as muscle weakness, wasting, cramps and stiffness of arms or legs; problems with speech or swallowing or, more rarely, with breathing. As the disease progresses, the pattern of symptoms and signs becomes similar, with increasing muscle weakness in the person's arms and legs, problems swallowing and communicating, and weakness of the muscles used for breathing, which ultimately leads to death. Most people die within 2-3 years of developing symptoms, but 25% are alive at 5 years and 5-10% at 10 years. The most common type of MND is amyotrophic lateral sclerosis (ALS). There are rarer forms, such as progressive muscular atrophy or primary lateral sclerosis, which may have a slower rate of progression.
Every person with MND has an individual progression of the disease. About 10-15% of people with MND will show signs of frontotemporal dementia, which causes cognitive dysfunction and issues in decision-making. A further 35% of people with MND show signs of mild cognitive change, which may affect their ability to make decisions and plan ahead.
MND can affect adults of any age, but mainly affects people aged 55 to 79. There are approximately 4,000 people with MND in England and Wales at any one time. The cause is unknown. About 5-10% of people with MND have a family history of the disease, and several abnormal genes have been identified.
There is no cure for MND. Therefore, care focuses on maintaining functional ability and enabling people with MND and their family members to live as full a life as possible.
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The quality standard is expected to contribute to improvements in the following outcomes: quality of life functional ability patient-reported outcome: symptoms patient-and carer-reported outcome: satisfaction with care and support provided survival from onset of symptoms.
How this quality standard supports delivery of outcome frameworks
NICE quality standards are a concise set of prioritised statements designed to drive measurable improvements in the 3 dimensions of quality -safety, experience and effectiveness of care -for a particular area of health or care. They are derived from high-quality guidance, such as that from NICE or other sources accredited by NICE. This quality standard, in conjunction with the guidance on which it is based, should contribute to the improvements outlined in the following 3 outcomes Tables 1-3 show the outcomes, overarching indicators and improvement areas from the frameworks that the quality standard could contribute to achieving.
T Table 1 NICE has developed guidance and an associated quality standard on patient experience in adult NHS services (see the NICE pathway on patient experience in adult NHS services), which should be considered alongside this quality standard. They specify that people receiving care should be treated with dignity, have opportunities to discuss their preferences, and be supported to understand their options and make fully informed decisions. They also cover the provision of information to people using services. Quality statements on these aspects of patient experience are not usually included in topic-specific quality standards. However, recommendations in the development sources for quality standards that affect people's experience of using services and are specific to the topic are considered during quality statement development.
Coordinated services
A person-centred, integrated approach to providing services is fundamental to delivering high-quality care to people with MND. Services should be commissioned from, and coordinated across, all relevant agencies encompassing the whole MND care pathway.
The Health and Social Care Act 2012 sets out a clear expectation that the care system should consider NICE quality standards in planning and delivering services, as part of a general duty to secure continuous improvement in quality. Commissioners and providers of health and social care
should refer to the library of NICE quality standards when designing high-quality services. Other quality standards that should also be considered when choosing, commissioning or providing a high-quality MND service are listed in related NICE quality standards.
T Tr raining and competencies aining and competencies
The quality standard should be read in the context of national and local guidelines on training and 
Rationale
Receiving a diagnosis of MND is distressing for a person, and they (and their family members or carers) are likely to have a variety of questions and concerns. MND is rare and most healthcare professionals will have little experience and knowledge of it. A consultant neurologist with expertise in treating people with MND can provide accurate and up-to-date information on the diagnosis, prognosis and management of MND with compassion and understanding.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that people diagnosed with MND are given information about the diagnosis, prognosis and management of MND by a consultant neurologist with expertise in MND.
Data sour
Data source: ce: Local data collection.
Process Process
Of adults with MND, the number who are given information at diagnosis about the diagnosis, prognosis and management of MND by a consultant neurologist with expertise in treating people with MND.
Data sour Data source: ce:
Local data collection based on extracts from or reviews of individual care records. At provider or clinical commissioning group level, data collection will involve small numbers.
Outcome Outcome a) Adults diagnosed with MND understand how the condition is likely to affect them. 
What the quality statement means for patients, service users and carers
Adults with MND Adults with MND are regularly checked to see if they are having any problems with their breathing.
These checks should happen when they are diagnosed with MND (or shortly afterwards) and then in regular appointments with a team of specialists called an MND multidisciplinary team (usually every 2-3 months). Adults with MND who are having difficulty breathing are offered non-invasive ventilation using a portable ventilator -a machine that supports the person's breathing. Decisions about non-invasive ventilation are shared between the multidisciplinary team, the respiratory ventilation service and the person with MND.
Source guidance
Motor neurone disease (2016) NICE guideline NG42, recommendations 1.5.3, 1.12.1, 1.12.2, 1.14.7, and 1.14.8-1.14.15
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Definitions of terms used in this quality statement

Non-in Non-invasiv vasive v e ventilation entilation
Non-invasive ventilation refers to methods of providing ventilatory support to a patient without placing an artificial airway in the main windpipe (trachea). This is usually achieved by fitting a mask covering the nose, or mouth and nose, or using nasal tubes or a mouthpiece, which is connected to a ventilator by tubing. The ventilator detects when the patient tries to take a breath in and delivers an extra flow of air to increase the volume of air inhaled. [Adapted from Motor neurone disease (NICE guideline NG42), recommendations 1.14.7, 1.14.8 and 1.14.10, and expert opinion]
Respiratory function tests to be undertaken at diagnosis and ongoing assessment are those detailed in motor neurone disease (NICE guideline NG42), section 1.14.
Symptoms and signs monitored in an assessment to detect potential respiratory impairment are set out in box 1 motor neurone disease (NICE guideline NG42), recommendation 1.14.7.
Assessment in the context of this statement also includes assessment of bulbar function, because this affects the type tests performed and the response to NIV.
[Motor neurone disease (NICE guideline NG42), recommendations 1.14.9, 1.14.18; expert opinion]
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Assessment for potential respiratory impairment includes monitoring cough effectiveness (weak cough being a sign of potential respiratory impairment) potentially by measuring cough peak flow.
[Motor neurone disease (NICE guideline NG42), recommendation 1.14.7; expert opinion]
Quality statement 3: Pro Quality statement 3: Provision of equipment and adaptions based on vision of equipment and adaptions based on multidisciplinary team assessment multidisciplinary team assessment
Quality statement
Adults with motor neurone disease (MND) receive tailored equipment and adaptions without delay, based on regular multidisciplinary team assessments.
Rationale
People with MND can have multiple functional problems and may therefore have complex equipment needs that will change as MND progresses. Regular assessment by the MND multidisciplinary team can ensure the provision of equipment and adaptations is responsive to a person's changing needs. Providing equipment and adaptions without delay maximises the impact on the person's quality of life, allowing them to continue with usual activities and reduce the likelihood of harm from adverse events such as falls. 
Quality measures
Data sour Data source: ce:
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b) The length of time in days between an equipment need or an adaption need being identified in a comprehensive multidisciplinary team assessment, and the equipment being provided or adaption made. 
Data sour
What the quality statement means for service providers, healthcare professionals and social care practitioners, and commissioners
Service pro Service providers viders (such as MND multidisciplinary teams) ensure that they assess people's needs, including mobility and daily living needs and abilities every 2-3 months, and that services are integrated between providers so that equipment and adaptions can be provided to meet people's changing needs without delay.
Healthcare professionals and social care pr Healthcare professionals and social care practitioners actitioners (such as members of MND multidisciplinary teams) ensure that they assess and anticipate changes in the person's needs, including mobility and daily living needs and abilities, every 2-3 months, and provide, or refer to services that can provide, equipment and adaptions to meet the person's individual needs without delay.
Commissioners Commissioners (such as clinical commissioning groups and NHS England) ensure that they commission MND services in which MND multidisciplinary teams assess people's needs,
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encompassing mobility and daily living needs and abilities, every 2-3 months, and provide tailored equipment and adaptions without delay.
What the quality statement means for patients, service users and carers
Adults with MND Adults with MND have regular checks to make sure that any equipment they have been given to help them manage their condition, such as a wheelchair, is still meeting their needs. These checks also help to anticipate any future changes in their needs, including whether any changes to existing equipment or new equipment will be needed. The checks should happen in appointments with a team of specialists called an MND multidisciplinary team (usually every 2-3 months).
Source guidance
Motor neurone disease (2016) NICE guideline NG42, recommendations 1.5.3, 1.9.1, 1.9.2 and 1.9.6
Definitions of terms used in this quality statement T Tailored equipment and adaptions ailored equipment and adaptions
Daily living aids, assistive technology and adaptions that can be integrated and adapted to meet the changing needs of the person with MND and their family or carers. Examples include wheelchairs, hoists, head supports, arm supports, riser-recliner chairs, drinking and eating aids, environmental controls, and home adaptions.
[Motor neurone disease (NICE guideline NG42), recommendations 1.9.5, 1.9.6 and 1.9.7]
Regular assessments Regular assessments
Assessments carried out by the multidisciplinary team every 2-3 months unless the person's symptoms and needs require more or less frequent assessment. Assessments cover the areas set out in recommendation 1.5.3 in NICE's guideline on motor neurone disease that include mobility and activities of daily living, communication, nutritional intake, swallowing, muscle problems, physical function, pain, respiratory function, cognition and behaviour, and social care needs.
Assessments include assessing and anticipating changes in the person's daily living needs, taking into account:
activities of daily living, including personal care, dressing and bathing, housework, shopping,
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food preparation, eating and drinking, and ability to continue with current work and usual activities mobility and avoiding falls and problems from loss of dexterity the home environment and the need for adaptations the need for assistive technology, such as environmental control systems a person's ability to use equipment.
[Adapted from Motor neurone disease (NICE guideline NG42), recommendations 1.5.2, 1.5.6, 1.9.1 and 1. 
Quality measures
Evidence of local arrangements to ensure that adults with MND receive personal care and support from a consistent team of care workers who are familiar with their needs.
Data sour
Process Process a) Number of workers providing personal care and support for an adult with MND.
Data sour Data source: ce:
Local data collection based on extracts from or reviews of individual care records. At provider or local authority group level, data collection will involve small numbers.
b) Number of first visits of workers providing personal care and support for an adult with MND.
Data sour
Data source: ce: Local data collection based on extracts from or reviews of individual care records. At provider or local authority group level, data collection will involve small numbers.
Outcome Outcome a) Adults with MND feel they receive the personal care and support they need. 
Source guidance
Motor neurone disease (2016) NICE guideline NG42, recommendation 1.6.5
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Quality measures
Structure Structure
Evidence of local arrangements to ensure that adults with MND are given opportunities to discuss their preferences and concerns about end of life care at diagnosis and key stages of disease progression.
Data sour
Process Process a) Of adults with MND, the number given opportunities to discuss their preferences and concerns about end of life care at diagnosis.
Data source: ce: Local data collection based on extracts from or reviews of individual care records. At provider or clinical commissioning group level, data collection will involve small numbers.
b) Of adults with MND, the number given opportunities to discuss their preferences and concerns about end of life care at key stages of disease progression. Sensitivity is needed regarding to the timing of discussions, and the person's current communication ability, cognitive status and mental capacity should be taken into account.
[Adapted from Motor neurone disease (NICE guideline NG42), recommendations 1.7.1 and 1.7.3] K Ke ey stages of the disease progression y stages of the disease progression Key stages of the disease progression include significant changes in the condition of the person with MND, and the trigger points set out in the guideline recommendation:
when there is a significant change in respiratory function when interventions such as gastrostomy or non-invasive ventilation are needed.
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Using the quality standard Using the quality standard
Quality measures
The quality measures accompanying the quality statements aim to improve the structure, process and outcomes of care in areas identified as needing quality improvement. They are not a new set of targets or mandatory indicators for performance management.
We have indicated if current national indicators exist that could be used to measure the quality statements. If there is no national indicator that could be used to measure a quality statement, the quality measure should form the basis for audit criteria developed and used locally.
See NICE's what makes up a NICE quality standard? for further information, including advice on using quality measures.
Levels of achievement
Expected levels of achievement for quality measures are not specified. Quality standards are intended to drive up the quality of care, and so achievement levels of 100% should be aspired to (or 0% if the quality statement states that something should not be done). However, NICE recognises that this may not always be appropriate in practice, taking account of safety, choice and professional judgement, and therefore desired levels of achievement should be defined locally.
NICE's quality standard service improvement template helps providers to make an initial assessment of their service compared with a selection of quality statements. It includes assessing current practice, recording an action plan and monitoring quality improvement. This tool is updated monthly to include new quality standards.
Using other national guidance and policy documents
Other national guidance and current policy documents have been referenced during the development of this quality standard. It is important that the quality standard is considered alongside the documents listed in development sources.
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Div Diversity ersity, equality and language , equality and language Commissioners and providers should aim to achieve the quality standard in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this quality standard should be interpreted in a way that would be inconsistent with compliance with those duties.
